Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.70 |
| ▸ | NPC1 | O15118 | 6/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756247 | 0.92 | RAB9A (0.81) | RAB9ANPC1MEN1KMT2ATP53 | |
| SCHEMBL7904977 | 0.83 | RAB9A (0.52) | RAB9ANPC1MEN1KMT2ATDP1 | |
| SCHEMBL1275920 | 0.83 | ALDH1A1 (0.70) | RAB9ANPC1MEN1KMT2ATDP1 | |
| SCHEMBL13141239 | 0.82 | NPC1 (0.68) | RAB9ANPC1MEN1KMT2ATP53 | |
| SCHEMBL25750063 | 0.82 | RAB9A (0.68) | RAB9ANPC1MEN1KMT2ATDP1 | |
| SCHEMBL15946354 | 0.82 | NPC1 (0.68) | RAB9ANPC1MEN1KMT2ATP53 | |
| SCHEMBL13234045 | 0.82 | NPC1 (0.68) | RAB9ANPC1MEN1KMT2ATP53 | |
| SCHEMBL13377396 | 0.82 | NPC1 (0.68) | RAB9ANPC1MEN1KMT2ATP53 | |
| SCHEMBL420210 | 0.82 | MAPT (0.76) | RAB9ANPC1MEN1KMT2ATDP1 | |
| SCHEMBL13993509 | 0.82 | MAPT (0.61) | RAB9ANPC1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | claimed |
| US-6624152-B2 | Inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention relates to pharmaceutical formulations comprising these compounds and methods of using them for inflammatory and autoimmune diseases | BIOGEN, INC. | 2003-09-23 | — | — | US | claimed |
| US-20030083267-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2003-05-01 | — | — | US | claimed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | claimed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | claimed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | claimed |
| US-6306840-B1 | ANTISTICKING AGENTS OF OLIGOPEPTIDES | BIOGEN, INC. | 2001-10-23 | — | — | US | claimed |
| US-20210163404-A1 | NOVEL UREA COMPOUNDS AND BIOISOSTERES THEREOF AND THEIR USE FOR TREATING INFLAMMATION AND INFLAMMATION-RELATED PATHOLOGIES | UNIVERSITé LAVAL (CA) | 2021-06-03 | — | — | US | disclosed |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-9464064-B2 | HCV helicase inhibitors and methods of use thereof | UNIVERSITY OF KANSAS (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140227225-A1 | HCV Helicase Inhibitors and Methods of Use Thereof | UWM RESEARCH FOUNDATION, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20060166866-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-6624152-B2 | Inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention relates to pharmaceutical formulations comprising these compounds and methods of using them for inflammatory and autoimmune diseases | BIOGEN, INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030083267-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2003-05-01 | — | — | US | disclosed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | disclosed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | disclosed |
| US-6306840-B1 | ANTISTICKING AGENTS OF OLIGOPEPTIDES | BIOGEN, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1142867-A2 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166866-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | RAB9A 1779/4885NPC1 2649/4885MEN1 1437/4885 |
| US-20140227225-A1 | HCV Helicase Inhibitors and Methods of Use Thereof | DHX15, DDX5, DHX35 | RAB9A 3431/4885NPC1 2518/4885MEN1 4398/4885 |
| US-20210163404-A1 | NOVEL UREA COMPOUNDS AND BIOISOSTERES THEREOF AND THEIR USE FOR TREATING INFLAMMATION AND INFLAMMATION-RELATED PATHOLOGIES | NOS3, NOS2, CBS | RAB9A 2066/4885NPC1 3690/4885MEN1 4239/4885 |
| US-20030083267-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | RAB9A 1779/4885NPC1 2649/4885MEN1 1437/4885 |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | RAB9A 3832/4885NPC1 2350/4885MEN1 2234/4885 |
| US-20030018016-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | RAB9A 1779/4885NPC1 2649/4885MEN1 1437/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | RAB9A 3832/4885NPC1 2350/4885MEN1 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.